Category
Other
The latest reporting, analysis, and field notes from across the Other beat.
When an FDA Nod Becomes a Signal Fire: Leucovorin, Autism Hope, and the Policy Vacuum
On Sept. 22, 2025, the U.S.
Approval Without a Roadmap: How the FDA’s Leucovorin Move Opened an Information Vacuum and a Market of Hope
When the FDA cleared leucovorin calcium for cerebral folate deficiency on Sept. 22, thousands of parents poured into a single Facebook group looking for dosage charts, prescribers and hope.
When an FDA Nod Meets a Facebook Frenzy: Leucovorin, Autism, and the Policy Risks of Hope
On Sept. 22, 2025, an FDA decision to approve leucovorin calcium tablets for cerebral folate deficiency rippled far beyond regulators: tens of thousands of parents flooded online groups, clinicians were swamped with requests, and a chaotic patchwork of advice filled the gap left by federal guidance.
When a Drug Becomes a Promise: Leucovorin, Facebook, and the Thin Line Between Hope and Hype
Within hours of the FDA relabeling leucovorin for cerebral folate deficiency, tens of thousands of parents flooded a Facebook group seeking answers — dosage, doctors, success stories and conspiracies. The scramble reveals more than online chaos; it exposes how policy, limited evidence, and social media converge to remake hope into de facto clinical guidance.